Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

April 10th 2025

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
Immune Microenvironment a Key Target in CLL

April 8th 2025

Patient visit with pharmacist | Image credit : Chinnapong – stock.adobe.com
Pharmacist-Led Model Reduces Tumor Lysis Risk in CLL Venetoclax Therapy

April 3rd 2025

Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com
In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib

March 20th 2025

More News

Cancer cell and lymphocytes | Image credit: Christoph Burgstedt-stock.adobe.com
February 28th 2024

CLL Cells Found to Secrete IL-9, Hindering Cytotoxic T-Cell Function

Jared Kaltwasser
Investigators say the findings could lead to new therapeutic targets.
Medication Management | Image Credit: © siripimon2525 - stock.adobe.com
February 24th 2024

Discontinuation of Ibrutinib Is Common in Older Patients With CLL, Study Finds

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.
Cancer care representation | Image credit: Nikki Zalewski - stock.adobe.com
February 19th 2024

Access to Cancer Care Alleviates Racial Disparities in CLL/SLL

Gwen Mergian
No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.
Social Determinants of Health - STOATPHOTO - stock.adobe.com
February 16th 2024

Social Deprivation Independently Impacts Outcomes in Patients With Chronic Lymphocytic Leukemia

Luke Halpern
The study was the first of its kind to analyze social deprivation among CLL patients and observe the underlying reasons behind their clinical outcomes.
Lung imaging | Image credit: as-artmedia - stock.adobe.com
February 14th 2024

Mass-Like Opacities on Imaging Linked With LPI in CLL

Jared Kaltwasser
Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found.
Leukemia test against a background of medical test tubes | Image credit: syhin_stas - stock.adobe.com
February 9th 2024

Analysis: More Than Half of CLL/SLL Cases Diagnosed After 2018 Received Targeted Therapy

Jared Kaltwasser
The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing.
Questionnaire | Image credit: Richelle - stock.adobe.com
February 6th 2024

Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL

Jared Kaltwasser
Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.
leukemia disease concept - vector illustration Image credit: chrupka - stock.adobe.com
February 4th 2024

Active Hexose-Correlated Compound Shows Effectiveness in CLL

Luke Halpern
Efficacy against chronic lymphocytic leukemia (CLL) was seen when tested as both a single agent and in combination with antitumor antibody.
Chronic lymphocytic leukemia cells in blood flow-isometric view | Image credit: LASZLO - stock.adobe.com
January 26th 2024

In CLL, BTK-Inhibitor Resistance Remains a Confounding Problem

Jared Kaltwasser
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).
Chronic lymphocytic leukemia | Image credit: momius - stock.adobe.com
January 23rd 2024

Study: CLL Therapies Cannot Overcome Increased Infection, Malignancy Risk

Jared Kaltwasser
A new report compared the blood immune repertoires of patients with chronic lymphocytic leukemia (CLL) who received chemoimmunotherapy and those who received ibrutinib.
SAP logo | image credit: AJMC
January 20th 2024

ASH Abstracts Showcase Effective Treatments for MM, CLL, FL

Skylar Jeremias
Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Cancer treatment, doctor supporting patient | Image credit: catalin - stock.adobe.com
January 19th 2024

Real-World Study Confirms Efficacy of Venetoclax Alone, After BTKi Therapy in CLL

Skylar Jeremias
Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).
EBO logo
January 17th 2024

Data Reveal Racial, SDOH Factors Linked to OS Differences in CLL

Interview by Mary Caffrey
Chronic lymphocytic leukemia - LASZLO - stock.adobe.com
January 12th 2024

Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL

Rose McNulty
A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Chronic lymphocytic leukemia in blood | Image credit: LASZLO - stock.adobe.com
January 10th 2024

Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups

Rose McNulty
Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
Image credit: jarun011 - stock.adobe.com
January 5th 2024

Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era

Rose McNulty
An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
CLL Society’s Koffman Says ASH 2023 Offered “Evolutionary” Changes
January 2nd 2024

CLL Society’s Koffman Says ASH 2023 Offered “Evolutionary” Changes

Interview by Mary Caffrey
Jaypirca | Image credit: Eli Lilly
December 2nd 2023

FDA Grants Accelerated Approval to Pirtobrutinib for Patients With CLL/SLL After Use of BTK, BCL-2 Inhibitors

Mary Caffrey
The therapy is already approved for certain patients with relapsed/refractory mantle cell lymphoma.
Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy
August 3rd 2023

Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy

Mary Caffrey
Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.
Health data on computer
June 11th 2023

Researchers Deliver Updates on Efforts Toward Eradicating CLL

Christina Mattina
Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.
Balancing pros and cons
June 10th 2023

Long-Term Data Show QOL Advantage of Zanubrutinib in 3 Cancers

Christina Mattina
Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo